Edding Group Company Limited 仍注册 报告 监控 中国香港 113 15小时41分钟前更新 公司编号:F0028498 股本:- 注册日期:2020-09-22 电话:- 邮箱:- 网址:- 地址: 香港九龙海港城港威大厦六座33楼3306室,中国上海万荣路700号A3栋122–129单元 简介:Edding Group Company Limited,成立于2020年,位于香港特别行...
We are an ideal gateway partner for global pharmaceutical MNCs. We create value for our partners through fast and high-quality drug development by leveraging our China-focused drug development capabilities and global-standard management and operating systems. ...
We are building two inhalation technology platforms for nebulizer suspension and DPI drugs. The technology for the manufacturing of FPN was transferred to us in 2022. In the same year, we completed construction of the manufacturing facility for FPN and submitted manufacturing application to the NMPA...
Edding is a leading integrated pharmaceutical company in China. Edding’s vision is to become a leading ‘Global for China' pharmaceutical company focusing on three core therapeutic areas, namely anti-infectives, cardiovascular disease and respiratory system, by leveraging Edding’s market-tested full ...
Our company Vision History Core Therapeutic Areas Anti-infectives Cardiovascular Respiratory Others Full Value Chain Research & Development Manufacturing & Global Supply Chain Commercial Platform Career Talent recruitment 简 繁 Unit 122-129, Building A3, No. 700, Wanrong Road, Shanghai,China ...
近日,亿腾医药(Edding Group Company Limited)向港交所主板递交上市申请,摩根士丹利及瑞信为联席保荐人。 亿腾医药(Eddingpharm)于2001年在香港成立,中国管理总部位于上海,2008年开始与排在辉瑞和强生之后的全球第三大制药公司——GSK合作于中国推广及销售西力欣针剂及西力欣片剂。目前,亿腾在全国组建了一支拥有1,000个...
VASCEPA® (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the U.S. FDA comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA® was initially launched in the United States in 2013 based on the dr...
2021年6月25日,香港交易所披露了Edding Group Company Limited (下称“亿腾医药”)通过聆讯的招股书,其将很快在香港挂牌上市。亿腾医药此前分别于2020年9月23日、2021年3月29日在港交所递交招股书,摩根士丹利、瑞信为其联席保荐人。 亿腾医药,为中国领先的综合医药公司,愿景是凭借公司经市场验证的完整价值链能力...
2021年6月25日,香港交易所披露了Edding Group Company Limited (下称“亿腾医药”)通过聆讯的招股书,很快在香港挂牌上市。网页链接。 亿腾医药,为中国领先的综合医药公司,愿景是凭借公司经市场验证的完整价值链能力,成为专注于抗感染、心血管疾病(「CVD」)、呼吸系统三个核心治疗领域「放眼全球、服务中国」(Global fo...
2021年12月15日,来自上海的亿腾医药集团有限公司 Edding Group Company Limited (下称“亿腾医药”) 向港交所递交招股书,拟在香港主板 IPO上市。亿腾医药此前于2020年9月23日、2021年3月29日先后两次递交招股书,后于2021年6月25日通过港交所聆讯,未启动招股后失效。亿腾